Cargando…

Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression

Diabetes mellitus significantly contributes to breast cancer progression, where hyperglycemia upregulates specific genes, leading to more aggressive tumor growth. In patients with BC that develop diabetes, neuregulin 1 (NRG1) and epidermal growth factor receptor 3 (ERBB3) overexpression exacerbate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Marafie, Sulaiman K., Alshawaf, Eman, Abu-Farha, Mohamed, Thanaraj, Thangavel Alphonse, Wei, Dong-Qing, Al-Mulla, Fahd, Khan, Abbas, Abubaker, Jehad, Mohammad, Anwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374477/
https://www.ncbi.nlm.nih.gov/pubmed/37389721
http://dx.doi.org/10.1007/s12539-023-00566-y
_version_ 1785078784583532544
author Marafie, Sulaiman K.
Alshawaf, Eman
Abu-Farha, Mohamed
Thanaraj, Thangavel Alphonse
Wei, Dong-Qing
Al-Mulla, Fahd
Khan, Abbas
Abubaker, Jehad
Mohammad, Anwar
author_facet Marafie, Sulaiman K.
Alshawaf, Eman
Abu-Farha, Mohamed
Thanaraj, Thangavel Alphonse
Wei, Dong-Qing
Al-Mulla, Fahd
Khan, Abbas
Abubaker, Jehad
Mohammad, Anwar
author_sort Marafie, Sulaiman K.
collection PubMed
description Diabetes mellitus significantly contributes to breast cancer progression, where hyperglycemia upregulates specific genes, leading to more aggressive tumor growth. In patients with BC that develop diabetes, neuregulin 1 (NRG1) and epidermal growth factor receptor 3 (ERBB3) overexpression exacerbate tumor growth and progression. Since the interaction between NRG1 and ERBB3 is critical for tumor growth, understanding the molecular mechanisms underlying NRG1–ERBB3 complex formation is essential for elucidating diabetes-assisted breast cancer progression. However, the key residues forming the NRG1–ERBB3 complex remain unknown. Here, we substituted specific residues in NRG1 with alanine and studied its interactions with ERBB3 using computational structural biology tools. We further screened the South African natural compounds database to target the complex’s interface residues to discover potential inhibitors. The conformational stability and dynamic features of NRG1–WT, –H2A, –L3A, and –K35A complexed with ERBB3 were subjected to 400 ns molecular dynamics simulations. The free binding energies of all NRG1–ERBB3 complexes were calculated using the molecular mechanics-generalized Born surface area (MM/GBSA). The H2 and L3 alanine substitutions caused a loss of interaction with ERBB3 residue D73, weakening the interaction with ERBB3. Screening 1300 natural compounds identified four (SANC00643, SANC00824, SANC00975, and SANC00335) with the best potential to inhibit ERRB3-NRG1 coupling. The binding free energies for each complex were − 48.55 kcal/mol for SANC00643, − 47.68 kcal/mol for SANC00824, − 46.04 kcal/mol for SANC00975, and − 45.29 kcal/mol for SANC00335, showing their overall stronger binding with ERBB3 than NRG1 and their potential to act as ERBB3-NRG1 complex inhibitors. In conclusion, this complex may represent a residue-specific drug target to inhibit BC progression. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12539-023-00566-y.
format Online
Article
Text
id pubmed-10374477
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-103744772023-07-29 Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression Marafie, Sulaiman K. Alshawaf, Eman Abu-Farha, Mohamed Thanaraj, Thangavel Alphonse Wei, Dong-Qing Al-Mulla, Fahd Khan, Abbas Abubaker, Jehad Mohammad, Anwar Interdiscip Sci Original Research Article Diabetes mellitus significantly contributes to breast cancer progression, where hyperglycemia upregulates specific genes, leading to more aggressive tumor growth. In patients with BC that develop diabetes, neuregulin 1 (NRG1) and epidermal growth factor receptor 3 (ERBB3) overexpression exacerbate tumor growth and progression. Since the interaction between NRG1 and ERBB3 is critical for tumor growth, understanding the molecular mechanisms underlying NRG1–ERBB3 complex formation is essential for elucidating diabetes-assisted breast cancer progression. However, the key residues forming the NRG1–ERBB3 complex remain unknown. Here, we substituted specific residues in NRG1 with alanine and studied its interactions with ERBB3 using computational structural biology tools. We further screened the South African natural compounds database to target the complex’s interface residues to discover potential inhibitors. The conformational stability and dynamic features of NRG1–WT, –H2A, –L3A, and –K35A complexed with ERBB3 were subjected to 400 ns molecular dynamics simulations. The free binding energies of all NRG1–ERBB3 complexes were calculated using the molecular mechanics-generalized Born surface area (MM/GBSA). The H2 and L3 alanine substitutions caused a loss of interaction with ERBB3 residue D73, weakening the interaction with ERBB3. Screening 1300 natural compounds identified four (SANC00643, SANC00824, SANC00975, and SANC00335) with the best potential to inhibit ERRB3-NRG1 coupling. The binding free energies for each complex were − 48.55 kcal/mol for SANC00643, − 47.68 kcal/mol for SANC00824, − 46.04 kcal/mol for SANC00975, and − 45.29 kcal/mol for SANC00335, showing their overall stronger binding with ERBB3 than NRG1 and their potential to act as ERBB3-NRG1 complex inhibitors. In conclusion, this complex may represent a residue-specific drug target to inhibit BC progression. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12539-023-00566-y. Springer Nature Singapore 2023-06-30 2023 /pmc/articles/PMC10374477/ /pubmed/37389721 http://dx.doi.org/10.1007/s12539-023-00566-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research Article
Marafie, Sulaiman K.
Alshawaf, Eman
Abu-Farha, Mohamed
Thanaraj, Thangavel Alphonse
Wei, Dong-Qing
Al-Mulla, Fahd
Khan, Abbas
Abubaker, Jehad
Mohammad, Anwar
Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title_full Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title_fullStr Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title_full_unstemmed Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title_short Exploring the Binding Mechanism of NRG1–ERBB3 Complex and Discovery of Potent Natural Products to Reduce Diabetes-Assisted Breast Cancer Progression
title_sort exploring the binding mechanism of nrg1–erbb3 complex and discovery of potent natural products to reduce diabetes-assisted breast cancer progression
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374477/
https://www.ncbi.nlm.nih.gov/pubmed/37389721
http://dx.doi.org/10.1007/s12539-023-00566-y
work_keys_str_mv AT marafiesulaimank exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT alshawafeman exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT abufarhamohamed exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT thanarajthangavelalphonse exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT weidongqing exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT almullafahd exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT khanabbas exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT abubakerjehad exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression
AT mohammadanwar exploringthebindingmechanismofnrg1erbb3complexanddiscoveryofpotentnaturalproductstoreducediabetesassistedbreastcancerprogression